Adele Clarkson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11711212/publications.pdf

Version: 2024-02-01

63	4,167	94381	118793
papers	citations	37 h-index	62 g-index

63	63	63	5528
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Switch/sucroseâ€nonâ€fermentable (<scp>SWI</scp>/<scp>SNF</scp>) complex (<scp>SMARCA4</scp>,) Tj ETQq1 1 0.784314 rgBT / strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas. Histopathology, 2022, 80, 906-921.	1.6	9
2	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Modern Pathology, 2022, 35, 836-849.	2.9	20
3	PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours. Endocrine Pathology, 2021, 32, 408-414.	5.2	12
4	DNA damageâ€inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression. Histopathology, 2021, 79, 106-116.	1.6	8
5	NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomasâ€"a study of 4569 cases. Modern Pathology, 2020, 33, 924-932.	2.9	51
6	A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1419-1428.	2.1	46
7	When used together SS18â€"SSX fusionâ€specific and SSX Câ€terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases. Histopathology, 2020, 77, 588-600.	1.6	50
8	Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors. Endocrine Pathology, 2020, 31, 150-155.	5.2	15
9	Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. American Journal of Surgical Pathology, 2019, 43, 35-46.	2.1	74
10	Real world experience of BRAFV600E mutation specific immunohistochemistry in colorectal carcinoma. Pathology, 2018, 50, 342-344.	0.3	6
11	The epithelioid BAP1â€negative and p16â€positive phenotype predicts prolonged survival in pleural mesothelioma. Histopathology, 2018, 72, 509-515.	1.6	17
12	ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Human Pathology, 2018, 82, 249-257.	1.1	42
13	Immunohistochemical expression of somatostatin receptors SSTR2A and SSTR5 in 299 pituitary adenomas. Pathology, 2018, 50, 472-474.	0.3	4
14	NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRAS Q61R or KRAS Q61R Mutation in Colorectal Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 475-480.	0.6	11
15	Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized. American Journal of Surgical Pathology, 2017, 41, 1433-1442.	2.1	56
16	NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2. American Journal of Surgical Pathology, 2017, 41, 75-81.	2.1	31
17	Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy. Pathology, 2017, 49, 457-464.	0.3	34
18	Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2016, 11, e0150338.	1.1	11

#	Article	IF	Citations
19	Fumarate Hydrataseâ€“deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. American Journal of Surgical Pathology, 2016, 40, 599-607.	2.1	102
20	Immunoregulatory Forkhead Box Protein p3-Positive Lymphocytes Are Associated with Overall Survival in Patients with Pancreatic Neuroendocrine Tumors. Journal of the American College of Surgeons, 2016, 222, 281-287.	0.2	24
21	Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms. Pathology, 2016, 48, 319-324.	0.3	15
22	Loss of INI1 expression in colorectal carcinoma is associated with high tumor grade, poor survival, BRAFV600E mutation, and mismatch repair deficiency. Human Pathology, 2016, 55, 83-90.	1.1	20
23	Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma. Human Pathology, 2016, 57, 91-97.	1.1	19
24	Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Scientific Reports, 2016, 6, 26191.	1.6	162
25	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. Human Molecular Genetics, 2016, 25, ddw362.	1.4	26
26	Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. Pathology, 2016, 48, 336-340.	0.3	35
27	Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer. Modern Pathology, 2016, 29, 266-274.	2.9	39
28	Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	48
29	Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Human Pathology, 2016, 51, 9-15.	1.1	72
30	Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology, 2015, 47, 302-307.	0.3	102
31	A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2015, 39, 652-659.	2.1	85
32	Medullary Colorectal Carcinoma Revisited: A Clinical and Pathological Study of 102 Cases. Annals of Surgical Oncology, 2015, 22, 2988-2996.	0.7	45
33	Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Modern Pathology, 2015, 28, 1360-1368.	2.9	95
34	Increased SSTR2A and SSTR3 expression in succinate dehydrogenaseâ€“deficient pheochromocytomas and paragangliomas. Human Pathology, 2015, 46, 390-396.	1.1	58
35	ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 134-138.	0.6	27
36	Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer. PLoS ONE, 2014, 9, e87456.	1.1	38

#	Article	IF	Citations
37	A Further Investigation of Combined Mismatch Repair and BRAFV600E Mutation Specific Immunohistochemistry as a Predictor of Overall Survival in Colorectal Carcinoma. PLoS ONE, 2014, 9, e106105.	1.1	13
38	BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Modern Pathology, 2014, 27, 644-650.	2.9	53
39	EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 2014, 46, 501-508.	0.3	9
40	Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas. American Journal of Surgical Pathology, 2014, 38, 560-566.	2.1	71
41	BRAF V600E mutation specific immunohistochemistry with clone VE1 is not reliable in pituitary adenomas. Pathology, 2014, 46, 79-80.	0.3	7
42	Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1588-1602.	2.1	282
43	Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 2014, 46, 383-388.	0.3	32
44	Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Human Pathology, 2014, 45, 1697-1703.	1.1	61
45	Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Human Pathology, 2013, 44, 2711-2718.	1.1	80
46	Improving Diagnosis of Tumor-Induced Osteomalacia With Gallium-68 DOTATATE PET/CT. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 687-694.	1.8	100
47	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. American Journal of Surgical Pathology, 2013, 37, 1592-1602.	2.1	125
48	Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenaseâ€“deficient Gastrointestinal Stromal Tumors. American Journal of Surgical Pathology, 2013, 37, 226-233.	2.1	119
49	Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression. Modern Pathology, 2012, 25, 1307-1313.	2.9	46
50	The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination. Human Molecular Genetics, 2012, 21, 559-568.	1.4	85
51	Renal Tumors and Hereditary Pheochromocytoma-Paraganglioma Syndrome Type 4. New England Journal of Medicine, 2011, 364, 885-886.	13.9	120
52	Renal Tumors Associated With Germline SDHB Mutation Show Distinctive Morphology. American Journal of Surgical Pathology, 2011, 35, 1578-1585.	2.1	184
53	Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma: authorsâ€™ reply. Pathology, 2011, 43, 85-86.	0.3	0
54	Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types. American Journal of Surgical Pathology, 2010, 34, 636-644.	2.1	210

#	Article	IF	Citations
55	Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology, 2010, 42, 409-413.	0.3	114
56	Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Human Pathology, 2010, 41, 805-814.	1.1	235
57	Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 434-441.	1.8	120
58	Nuclear Accumulation of E-Cadherin Correlates with Loss of Cytoplasmic Membrane Staining and Invasion in Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1436-1442.	1.8	71
59	Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. Journal of Neuro-Oncology, 2008, 87, 71-78.	1.4	86
60	Wnt Pathway Inhibitors Are Strongly Down-Regulated in Pituitary Tumors. Endocrinology, 2008, 149, 1235-1242.	1.4	104
61	Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone, 2006, 39, 369-376.	1.4	26
62	Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. American Journal of Surgical Pathology, 2006, 30, 1140-1149.	2.1	213
63	Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4088-4094.	1.8	92